Long-term treatment effects of soticlestat in patients with Dravet syndrome or Lennox-Gastaut syndrome: interim data from the ENDYMION 1 trial

被引：0
|
作者：
Asgharnejad, M. [1 ]
Yao, Y. [1 ]
Dlugos, D. [2 ]
Mitra, P. [1 ]
Murthy, V. [1 ]
机构：
[1] Takeda Pharmaceut Co Ltd, Cambridge, MA USA
[2] Childrens Hosp Philadelphia, Philadelphia, PA USA
来源：
EPILEPSIA | 2023年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
470
引用
收藏
页码：291 / 291
页数：1
相关论文
共 50 条
  • [41] Long-term effects of 24-month treatment with vagus nerve stimulation on behaviour in children with Lennox-Gastaut syndrome
    Aldenkamp, AP
    Majoie, HJM
    Berfelo, MW
    Evers, SMAA
    Kessels, AGH
    Renier, WO
    Wilmink, J
    EPILEPSY & BEHAVIOR, 2002, 3 (05) : 475 - 479
  • [42] RUFINAMIDE AS ADD-ON TREATMENT FOR PATIENTS WITH LENNOX-GASTAUT SYNDROME
    Nakken, O.
    Eriksson, A.
    Lossius, M.
    Nakken, K.
    EPILEPSIA, 2009, 50 : 153 - 154
  • [43] Optimizing Clobazam Treatment in Patients with Lennox-Gastaut Syndrome (LGS)
    Wechsler, Robert
    Gidal, Barry
    Chung, Steve
    Peng, Guangbin
    Isojarvi, Jouko
    NEUROLOGY, 2016, 86
  • [44] Real-world data on the use of cannabidiol in patients with Lennox-Gastaut Syndrome or Dravet Syndrome in the UK early access programme
    Saravanai-Prabu, S.
    Eltze, C.
    Alshehhi, S.
    Al Ghfeli, A.
    Vyas, K.
    Gusto, G.
    Khachatryan, A.
    Martinez, M.
    Desurkar, A.
    EPILEPSIA, 2023, 64 : 517 - 517
  • [45] Long-term safety and efficacy of clobazam for Lennox-Gastaut syndrome: Interim results of an open-label extension study
    Ng, Yu-Tze
    Conry, Joan
    Paolicchi, Juliann
    Kernitsky, Lydia
    Mitchell, Wendy
    Drummond, Rebecca
    Isojarvi, Jouko
    Lee, Deborah
    Owen, Randall
    EPILEPSY & BEHAVIOR, 2012, 25 (04) : 687 - 694
  • [46] COST-EFFECTIVENESS OF CANNABIDIOL (CBD) FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH TREATMENT-RESISTANT LENNOX-GASTAUT SYNDROME OR DRAVET SYNDROME IN THE NETHERLANDS
    Siddiqui, J.
    Bowditch, S.
    VALUE IN HEALTH, 2023, 26 (12) : S127 - S128
  • [47] Safety and long-term effectiveness of new antiepileptic drugs in symptomatic lennox-gastaut syndrome
    Pauletto, G.
    Cecotti, L.
    Bassetti, M.
    Gigli, G.
    Bergonzi, P.
    EPILEPSIA, 2006, 47 : 121 - 121
  • [48] Long-term effectiveness of add-on perampanel in patients with Lennox-Gastaut syndrome: A multicenter retrospective study
    Matricardi, Sara
    Cesaroni, Elisabetta
    Bonanni, Paolo
    Foschi, Nicoletta
    D' Aniello, Alfredo
    Di Gennaro, Giancarlo
    Striano, Pasquale
    Cappanera, Silvia
    Siliquini, Sabrina
    Freri, Elena
    Ragona, Francesca
    Granata, Tiziana
    Deleo, Francesco
    Villani, Flavio
    Russo, Angelo
    Messana, Tullio
    Siri, Laura
    Bagnasco, Irene
    Vignoli, Aglaia
    Operto, Francesca Felicia
    Orsini, Alessandro
    Bonuccelli, Alice
    Papa, Amanda
    Peruzzi, Cinzia
    Liguori, Claudio
    Verrotti, Alberto
    Chiarelli, Francesco
    Marini, Carla
    Lattanzi, Simona
    EPILEPSIA, 2023, 64 (06) : E98 - E104
  • [49] Retrospective chart review study of use of cannabidiol (CBD) independent of concomitant clobazam in patients with Lennox-Gastaut syndrome or Dravet syndrome: Interim analysis
    Nortvedt, C.
    Bast, T.
    Pulitano, P.
    Soto, V.
    Toulouse, J.
    Fuller, D. S.
    EPILEPSIA, 2022, 63 : 134 - 134
  • [50] Recent Treatment Advances in Dravet Syndrome and Lennox-Gastaut Syndrome: Influence and Continuing Need for HCP and Caregiver Education
    Drexel, Carole
    del Nido, Elizabeth
    Turell, Wendy
    Thiele, Elizabeth
    NEUROLOGY, 2021, 96 (15)
12345